181 related articles for article (PubMed ID: 27826159)
21. Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation.
Yao X; Abraham NS; Sangaralingham LR; Bellolio MF; McBane RD; Shah ND; Noseworthy PA
J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27412905
[TBL] [Abstract][Full Text] [Related]
22. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack.
Coleman CI; Peacock WF; Bunz TJ; Alberts MJ
Stroke; 2017 Aug; 48(8):2142-2149. PubMed ID: 28655814
[TBL] [Abstract][Full Text] [Related]
23. Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II).
Steinberg BA; Shrader P; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Hylek E; Kowey PR; Mahaffey KW; O'Brien EC; Singer DE; Peterson ED; Piccini JP;
Am Heart J; 2017 Jul; 189():40-47. PubMed ID: 28625380
[TBL] [Abstract][Full Text] [Related]
24. When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multicentre prospective randomized study.
Yu HT; Shim J; Park J; Kim TH; Uhm JS; Kim JY; Joung B; Lee MH; Kim YH; Pak HN
Eur Heart J; 2019 May; 40(19):1531-1537. PubMed ID: 30590600
[TBL] [Abstract][Full Text] [Related]
25. [Stroke after discontinuation of new anticoagulants prior to surgery].
Myrstad M; Vandvik I; Engebretsen EH; Tveit A
Tidsskr Nor Laegeforen; 2017 Dec; 137(23-24):. PubMed ID: 29231667
[No Abstract] [Full Text] [Related]
26. Body Mass Index Influence on the Clinical Outcomes for Nonvalvular Atrial Fibrillation Patients Admitted to a Hospital Treated with Direct Oral Anticoagulants: A Retrospective Cohort Study.
Li X; Zuo C; Ji Q; Xue Y; Wang Z; Lv Q
Drug Des Devel Ther; 2021; 15():1931-1943. PubMed ID: 33986592
[TBL] [Abstract][Full Text] [Related]
27. Inappropriate doses of direct oral anticoagulants in real-world clinical practice: prevalence and associated factors. A subanalysis of the FANTASIIA Registry.
Ruiz Ortiz M; Muñiz J; Raña Míguez P; Roldán I; Marín F; Asunción Esteve-Pastor M; Cequier A; Martínez-Sellés M; Bertomeu V; Anguita M;
Europace; 2018 Oct; 20(10):1577-1583. PubMed ID: 29186393
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of indications for reduced-dose non-vitamin K antagonist oral anticoagulants in hospitalised patients with atrial fibrillation.
Jelonek O; Gorczyca I; Bączek M; Kośmider P; Wożakowska-Kapłon B
Kardiol Pol; 2018; 76(7):1073-1080. PubMed ID: 29441513
[TBL] [Abstract][Full Text] [Related]
29. Comparison of the Incidences of Complications After Second-Generation Cryoballoon Ablation of Atrial Fibrillation Using Vitamin K Antagonists Versus Novel Oral Anticoagulants.
Mugnai G; de Asmundis C; Iacopino S; Stroker E; Longobardi M; De Regibus V; Coutino-Moreno HE; Takarada K; Choudhury R; Abugattas de Torres JP; Storti C; Brugada P; Chierchia GB
Am J Cardiol; 2017 Jul; 120(2):223-229. PubMed ID: 28532773
[TBL] [Abstract][Full Text] [Related]
30. Suboptimal Use of Oral Anticoagulants in Atrial Fibrillation: Has the Introduction of Direct Oral Anticoagulants Improved Prescribing Practices?
Alamneh EA; Chalmers L; Bereznicki LR
Am J Cardiovasc Drugs; 2016 Jun; 16(3):183-200. PubMed ID: 26862063
[TBL] [Abstract][Full Text] [Related]
31. [New oral anticoagulants - sunset for warfarin in therapy of atrial fibrillation].
Koziński M; Obońska K; Kubica A; Navarese EP; Kubica J
Kardiol Pol; 2012; 70(10):1053-60. PubMed ID: 23080100
[No Abstract] [Full Text] [Related]
32. Effectiveness and Safety of Apixaban Versus Rivaroxaban for Patients With Atrial Fibrillation.
Ann Intern Med; 2020 Apr; 172(7):. PubMed ID: 32150747
[No Abstract] [Full Text] [Related]
33. [What role for the direct oral anticoagulants in oncology?].
Lebellec L; Kouakam C; Bertrand N; Penel N
Bull Cancer; 2018; 105(7-8):631-633. PubMed ID: 29960639
[No Abstract] [Full Text] [Related]
34. [Comparison of the cost-utility of direct oral anticoagulants for the prevention of stroke in patients with atrial fibrillation in Spain].
Monreal-Bosch M; Soulard S; Crespo C; Brand S; Kansal A
Rev Neurol; 2017 Mar; 64(6):247-256. PubMed ID: 28272725
[TBL] [Abstract][Full Text] [Related]
35. Uptake of novel oral anticoagulants in Australia.
Pratt NL; Ramsay EN; Caughey GE; Shakib S; Roughead EE
Med J Aust; 2016 Feb; 204(3):104-5.e1. PubMed ID: 26866544
[No Abstract] [Full Text] [Related]
36. Comparing the Cost Effectiveness of Non-vitamin K Antagonist Oral Anticoagulants with Well-Managed Warfarin for Stroke Prevention in Atrial Fibrillation Patients at High Risk of Bleeding.
Hospodar AR; Smith KJ; Zhang Y; Hernandez I
Am J Cardiovasc Drugs; 2018 Aug; 18(4):317-325. PubMed ID: 29740750
[TBL] [Abstract][Full Text] [Related]
37. Safety of dabigatran or rivaroxaban for thoracoscopic ablation in patients with atrial fibrillation.
Im SI; Jeong DS; Park SJ; Park KM; Huh J; Kim JS; On YK
Int J Cardiol; 2015; 186():213-5. PubMed ID: 25828118
[No Abstract] [Full Text] [Related]
38. Tromboc@t Working Group recommendations for management in patients receiving direct oral anticoagulants.
Olivera P; Gabilondo M; Constans M; Tàssies D; Plensa E; Pons V; Las Heras G; Jiménez C; Campoy D; Bustins A; Oliver A; Marzo C; Canals T; Varela A; Sorigue M; Sánchez E; Ene G; Perea G; Vicente L; López M; Cerdá M; Johansson E; Aguinaco MR; Santos N; Mateo J; Reverter JC; Moya Á; Santamaría A
Med Clin (Barc); 2018 Sep; 151(5):210.e1-210.e13. PubMed ID: 29602444
[TBL] [Abstract][Full Text] [Related]
39. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
Nielsen PB; Skjøth F; Søgaard M; Kjældgaard JN; Lip GY; Larsen TB
BMJ; 2017 Feb; 356():j510. PubMed ID: 28188243
[No Abstract] [Full Text] [Related]
40. Incorporating edoxaban into the choice of anticoagulants for atrial fibrillation.
Weitz JI; Eikelboom J
Thromb Haemost; 2016 Jan; 115(2):257-70. PubMed ID: 26466666
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
